Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
Alzheimer's & Dementia · 2025-04 · 21 (4)
DOI: 10.1002/alz.70062 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 02.04.2025. Verfasst von Hong Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Plaque, Amyloid. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
INTRODUCTION TRAILBLAZER‐ALZ 6 (NCT05738486) is a multicenter, double‐blind, ongoing phase 3b study in early symptomatic Alzheimer's disease. METHODS Participants ( n = 843) were randomized 1:1:1:1 (standard + three alternative donanemab dosing arms). Primary outcome was relative risk reduction (RRR) of amyloid‐related imaging abnormalities with edema/effusions (ARIA‐E) at 24 weeks assessed with Bayesian logistic regression. Amyloid plaque levels by positron emission tomography and serum donanemab pharmacokinetics were measured. RESULTS ARIA‐E frequencies for standard, modified titration, dose skipping, and C max arms were 23.7%, 13.7%, 18.6%, and 18.3%, respectively, at 24 weeks and similar at 52 weeks: 24.2%, 15.6%, 18.6%, and 18.8%, respectively. Modified titration met the 24‐week primary outcome with 94% probability of achieving ≥ 20% RRR versus the standard arm. Modified titration also had significantly lower ARIA‐E severity, but similar cumulative exposure and mean amyloid reduction compared to the standard arm. DISCUSSION Gradual up‐titration of dose significantly reduced ARIA‐E risk while demonstrating comparable pharmacokinetics/pharmacodynamics compared to standard dosing. Highlights In TRAILBLAZER‐ALZ 6, the amyloid‐related imaging abnormalities‐edema/effusions (ARIA‐E) frequency was 13.7% in the modified titration arm compared to 23.7% in the standard arm at week 24. The modified titration arm met the primary endpoint of ARIA‐E relative risk reduction at 24 weeks versus the standard arm. The modified titration versus standard arm at week 24 had comparable non‐ARIA‐E related safety profile, amyloid reduction, plasma phosphorylated tau217 reduction, cumulative exposure, and pharmacokinetics. Data at week 52 were consistent with week 24 results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Dementia Research Centre, Department of Neurodegenerative Disease, and the UK Dementia Research Institute, UCL Queen Square Institute of Neurology, London, UK.
- Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Butler Hospital, Providence, Rhode Island, USA.
- Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Förderung
- Eli Lilly and Company
Zitieren
APA
Wang, H., Serap Monkul Nery, E., Ardayfio, P., Khanna, R., Otero Svaldi, D., Gueorguieva, I., Shcherbinin, S., Andersen, S. W., Hauck, P. M., Engle, S. E., Brooks, D. A., Collins, E. C., Fox, N. C., Greenberg, S. M., Salloway, S., Mintun, M. A., & Sims, J. R. (2025). Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimer's & Dementia, 21(4). https://doi.org/10.1002/alz.70062
Vancouver
Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimer's & Dementia. 2025;21(4). doi:10.1002/alz.70062
BibTeX
@article{Wang2025,
author = {Wang, Hong and Serap Monkul Nery, Emel and Ardayfio, Paul and Khanna, Rashna and Otero Svaldi, Diana and Gueorguieva, Ivelina and Shcherbinin, Sergey and Andersen, Scott W and Hauck, Paula M and Engle, Staci E and Brooks, Dawn A and Collins, Emily C and Fox, Nick C and Greenberg, Steven M and Salloway, Stephen and Mintun, Mark A and Sims, John R},
title = {Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {4},
doi = {10.1002/alz.70062}
}
EUVIMED